Navigation Links
Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Date:6/5/2008

CALGARY, June 5 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it has started patient enrolment in a Phase II clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The principal investigator is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists. The primary objective of the Phase II trial is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity. The secondary objective is to determine the safety and tolerability of REOLYSIN(R) when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancer.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. Phase II combina
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... November 27 Stallergene...lair(R) in both adults and children,through a Mutu...ry where,Oralair(R) has been marketed, was the ref...registered in Austria, Belgium, Bulgaria, Cyprus, ...ce, Hungary, Ireland, Italy,Latvia, Lithuania, Lu...
(Date:11/25/2009)... Ambassador to Speak at Economic Club of Canada...) November 25, 2009 -- Ambassador to Speak at Econ...rench Ambassador for International Investment, and...To view a biography of David Appia go to www.inve...available to meet with press to discuss recent pro...
(Date:11/25/2009)..., Nov. 25 Ardea Bioscien...rry D. Quart, Pharm.D., president and chief execut...t Annual Health Care Conference. , ,Presentation ... Health Care Conference,Date: Tuesday, Decemb...ion: The New York Palace Hotel, New York, NY,Webc...
(Date:11/24/2009)...CRUZ, Calif., Nov. 24 Two more pre...r, the nation,s leading online job board and caree...hwestern and Columbia University are now members o...ce training Institutions. ,, The job board, ww... in the life sciences. While there are hundreds of...
Breaking Biology Technology:STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3French Ambassador for International Investment to Visit Toronto December 11 2Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2
... (ASX: CYT) JAK2 inhibitor CYT387 will be presente...rence in San Francisco. The talk will be presente... University and will overview the study of CYT387 ...rs. , , Full presentation details: , , ...n JAK2-V617F Induc e d MPD , 7am US PST, Tues...
...cember 5, Rosetta Genomics Ltd (Nasdaq: ROSG ), a...ostics and therapeutics, announced today,that it w... Conference on,Thursday, December 10, from 2:30-3:... A live audio webcast of the presentation will be ...y,s website, http://www.RosettaGenomics.com .,A r...
...generative medicine company developing solutions b...be featured in an upcoming segment of The Economic...for Biomedical Research series. , ...istogen, Inc., a regenerative medicine company dev... fibroblasts, will be featured in an upcoming segm...
Other Biology Technology:Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference 2Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference 3Histogen Featured on Economic Report Television Series 2
(Date:11/24/2009)...debate. A high-profile study a few years ago sugge...on from trees and leaves, evidence for a very clos...ems. , But new research from the University of W...ae provide a much richer diet for fish and other a...week in the Proceedings of the National Academy o...
(Date:11/23/2009)...plied mathematicians dissected the morphology of t...istic long leaf with a saddle-like arc midsection ...mple cause of the lily,s fan-like shapeelastic rel... growthwas revealed by using an equally simple tec...a postdoctoral student at Harvard,s School of Engi...
(Date:11/23/2009)...controvertible evidence" that the volcanic super-e...000 years ago deforested much of central India, so...ort. , The volcano ejected an estimated 800 cubi... crater (now the world,s largest volcanic lake) th...Ash from the event has been found in India, the In...
Breaking Biology News(10 mins):Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3The cause behind the characteristic shape of a long leaf revealed 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Encorium Group Amends LOI with Respect to the Sale of its U S Business 3B 49423 1Encorium Group Amends LOI with Respect to the Sale of its U S Business 3B 49423 2Encorium Group Amends LOI with Respect to the Sale of its U S Business 3B 49423 3Encorium Group Amends LOI with Respect to the Sale of its U S Business 3B 49423 4e Zassi com 28TM 29 Specialized Software Systems for the Medical Device Industry Named by LifeScience Alley 28R 29 As Preferred Provider 49419 1e Zassi com 28TM 29 Specialized Software Systems for the Medical Device Industry Named by LifeScience Alley 28R 29 As Preferred Provider 49419 2e Zassi com 28TM 29 Specialized Software Systems for the Medical Device Industry Named by LifeScience Alley 28R 29 As Preferred Provider 49419 3Work Stress for Mom Might Harm Baby 49415 1
...resent a “cautionary tale?about what may go wrong ...devise a diagnostic test for cancer. , In the Feb...er Institute, researchers from The University of T...perimental test intended to identify early ovarian...o lead to a reliable clinical test right away. , ...
... information that may help guide design of vaccine...ailed structural analysis of the complex formed by... target provides insight into why this particular ...istic for HIV discovered thus far. The research is...ccination has been a successful strategy for prote...
...ukemia in the United States was last reviewed by t... it was seen through the eyes of theories that dat...y invited three of the world,s foremost experts on...thoritative update covering the transformation in ...as occurred over the past decade. The review appea...
Other Biology News:Another Look Finds Promising Proteomics Test is Not Biologically Plausible 2Another Look Finds Promising Proteomics Test is Not Biologically Plausible 3Research advances quest for HIV-1 vaccine 2Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine 2
Mouse Anti-Human PPP2R2C Monoclonal Antibody, Unconjugated, Clone 6D1 from Novus Biologicals
Mouse Anti-Human BTG2 Polyclonal Antibody, Unconjugated from Novus Biologicals
Attofluor cell chamber from Molecular Probes (Invitrogen)
...A quantitation kit is used to quantitate double-st...ce of RNA or protein. With this kit, DNA is staine...th a VersaFluor or other fluorometer. The kit quan...crograms per ml and contains Hoechst 33258, calf t...
Biology Products: